Neurologic disturbances including encephalopathy, seizures, and focal deficits complicate the course 10-30% of patients undergoing organ or stem cell transplantation. While much or this morbidity is multifactorial and often associated with extra-cerebral dysfunction (e.g., graft dysfunction, metabolic derangements), immunosuppressive drugs also contribute significantly. This can either be through direct toxicity (e.g., posterior reversible encephalopathy syndrome from calcineurin inhibitors such as tacrolimus in the acute postoperative period) or by facilitating opportunistic infections in the months after transplantation. Other neurologic syndromes such as akinetic mutism and osmotic demyelination may also occur. While much of this neurologic dysfunction may be reversible if related to metabolic factors or drug toxicity (and the etiology is recognized and reversed), cases of multifocal cerebral infarction, hemorrhage, or infection may have poor outcomes. As transplant patients survive longer, delayed infections (such as progressive multifocal leukoencephalopathy) and post-transplant malignancies are increasingly reported.
Keyphrases
- stem cell transplantation
- patients undergoing
- oxidative stress
- end stage renal disease
- high dose
- drug induced
- early onset
- ejection fraction
- chronic kidney disease
- liver failure
- multiple sclerosis
- peritoneal dialysis
- traumatic brain injury
- prognostic factors
- cell therapy
- case report
- stem cells
- metabolic syndrome
- low dose
- hepatitis b virus
- adipose tissue
- mesenchymal stem cells
- insulin resistance
- brain injury